Objective:To evaluate the clinical efficacy and safety of Kuanxiong Aerosol(KXA)in patients with chest tightness and pain pre-hospital.Methods:The Chinese database[Chinese Biomedical Literature Service System(SinoMed),China National Knowledge Infrastructure(CNKI),China Science and Technology Journal Database(VIP),Wanfang Database],and English database(PubMed,EMbase,the Cochrane Library,and Web of Science)were searched for identifying randomized controlled trials(RCTs)associated with KXA for the treatment of chest pain from the time of database establishment to 1 August,2022.Primary outcomes included chest pain relief rate,electrocardiogram(ECG)remission rate,and the incidence of adverse reactions.The Meta-analysis,risk of bias evaluation,sensitivity analysis,and publication bias were conducted by RevMan 5.3 software.Results:A total of 19 studies with 2487 patients were included.The Meta-analysis results showed that the chest tightness and pain relief rate of KXA group was higher than that of control group(RR=1.15,95%CI 1.06-1.25,P =0.001).The ECG remission rate in KXA group was not statistically significant compared with that in the control group(RR=1.04,95%CI 0.99-1.10,P =0.14).The incidence of adverse reactions in KXA group was significantly lower than that of nitroglycerin and other conventional drugs(RR=0.41,95%CI 0.33-0.52,P<0.00001).But there were 2 studies mentioned the blind method(single blind),indicating a low quality of the included literature.Conclusion:Available evidence indicates that KXA can improve the chest tightness and pain relief rate,reduce the incidence of adverse reactions,but it does not increase the ECG remission rate.The methodology and quality of included RCT in this study were relatively low,therefore,strictly-designed randomized double-blind trials with large-sample are still needed to verify the clinical efficacy of KXA.
chest tightness and painKuanxiong Aerosolsystem evaluationMeta-analysis
维普
万方数据
